Healthcare provider Zydus Cadila, on Wednesday, announced the signing of a collaboration agreement with Turkey’s Eczacibasi Ilac Pazarlama, A.S., to market biotech products in the Turkish market.
The agreement involves import of biosimilars which are currently unavailable in that country, especially for the treatment of cancer, and also paves the way for a long-term collaboration to produce and launch new products in the market.
The agreement was signed at the headquarters of Eczacıbasi Holding located at Kanyon Ofis in Istanbul by Pankaj Patel, Chairman and Managing Director of Zydus Group, Sharvil Patel, Deputy Managing Director, Bülent Eczacıbaşı, Chairman of Eczacıbaşı Holding, Erdal Karamercan, CEO of Eczacıbaşı Group, and Elif Çelik, Eczacıbaşı Healthcare Group President, the Ahmedabad-based Zydus Cadila said in a statement here.